Literature DB >> 30996790

Deciphering the Nonsense Readthrough Mechanism of Action of Ataluren: An in Silico Compared Study.

Marco Tutone1, Ivana Pibiri1, Laura Lentini1, Andrea Pace1, Anna Maria Almerico1.   

Abstract

Ataluren was reported to suppress nonsense mutations by promoting the readthrough of premature stop codons, although its mechanism of action (MOA) is still debated. The likely interaction of Ataluren with CFTR-mRNA has been previously studied by molecular dynamics. In this work we extended the modeling of Ataluren's MOA by complementary computational approaches such as induced fit docking (IFD), quantum polarized ligand docking (QPLD), MM-GBSA free-energy calculations, and computational mutagenesis. In addition to CFTR-mRNA, this study considered other model targets implicated in the translation process, such as eukaryotic rRNA 18S, prokaryotic rRNA 16S, and eukaryotic Release Factor 1 (eRF1), and we performed a comparison with a new promising Ataluren analogue (NV2445) and with a series of aminoglycosides, known to suppress the normal proofreading function of the ribosome. Results confirmed mRNA as the most likely candidate target for Ataluren and its analogue, and binding energies calculated after computational mutagenesis highlighted how Ataluren's interaction with the premature stop codon could be affected by ancillary nucleotides in the genetic context.

Entities:  

Year:  2019        PMID: 30996790      PMCID: PMC6466511          DOI: 10.1021/acsmedchemlett.8b00558

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  23 in total

Review 1.  When the message goes awry: disease-producing mutations that influence mRNA content and performance.

Authors:  J T Mendell; H C Dietz
Journal:  Cell       Date:  2001-11-16       Impact factor: 41.582

2.  Structure-based computational database screening, in vitro assay, and NMR assessment of compounds that target TAR RNA.

Authors:  Kenneth E Lind; Zhihua Du; Koh Fujinaga; B Matija Peterlin; Thomas L James
Journal:  Chem Biol       Date:  2002-02

3.  Importance of accurate charges in molecular docking: quantum mechanical/molecular mechanical (QM/MM) approach.

Authors:  Art E Cho; Victor Guallar; Bruce J Berne; Richard Friesner
Journal:  J Comput Chem       Date:  2005-07-15       Impact factor: 3.376

4.  Translational bypass of nonsense mutations in zebrafish rep1, pax2.1 and lamb1 highlights a viable therapeutic option for untreatable genetic eye disease.

Authors:  Mariya Moosajee; Kevin Gregory-Evans; Charles D Ellis; Miguel C Seabra; Cheryl Y Gregory-Evans
Journal:  Hum Mol Genet       Date:  2008-09-22       Impact factor: 6.150

5.  Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis.

Authors:  Isabelle Sermet-Gaudelus; Kris De Boeck; Georges J Casimir; François Vermeulen; Teresinha Leal; Agnès Mogenet; Delphine Roussel; Janine Fritsch; Laurence Hanssens; Samit Hirawat; Nilsen L Miller; Scott Constantine; Allen Reha; Temitayo Ajayi; Gary L Elfring; Langdon L Miller
Journal:  Am J Respir Crit Care Med       Date:  2010-07-09       Impact factor: 21.405

Review 6.  Pharmaceutical therapies to recode nonsense mutations in inherited diseases.

Authors:  Hui-Ling Rose Lee; Joseph P Dougherty
Journal:  Pharmacol Ther       Date:  2012-07-20       Impact factor: 12.310

7.  A meta-analysis of nonsense mutations causing human genetic disease.

Authors:  Matthew Mort; Dobril Ivanov; David N Cooper; Nadia A Chuzhanova
Journal:  Hum Mutat       Date:  2008-08       Impact factor: 4.878

8.  PTC124 targets genetic disorders caused by nonsense mutations.

Authors:  Ellen M Welch; Elisabeth R Barton; Jin Zhuo; Yuki Tomizawa; Westley J Friesen; Panayiota Trifillis; Sergey Paushkin; Meenal Patel; Christopher R Trotta; Seongwoo Hwang; Richard G Wilde; Gary Karp; James Takasugi; Guangming Chen; Stephen Jones; Hongyu Ren; Young-Choon Moon; Donald Corson; Anthony A Turpoff; Jeffrey A Campbell; M Morgan Conn; Atiyya Khan; Neil G Almstead; Jean Hedrick; Anna Mollin; Nicole Risher; Marla Weetall; Shirley Yeh; Arthur A Branstrom; Joseph M Colacino; John Babiak; William D Ju; Samit Hirawat; Valerie J Northcutt; Langdon L Miller; Phyllis Spatrick; Feng He; Masataka Kawana; Huisheng Feng; Allan Jacobson; Stuart W Peltz; H Lee Sweeney
Journal:  Nature       Date:  2007-04-22       Impact factor: 49.962

9.  Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial.

Authors:  Eitan Kerem; Samit Hirawat; Shoshana Armoni; Yasmin Yaakov; David Shoseyov; Michael Cohen; Malka Nissim-Rafinia; Hannah Blau; Joseph Rivlin; Micha Aviram; Gary L Elfring; Valerie J Northcutt; Langdon L Miller; Batsheva Kerem; Michael Wilschanski
Journal:  Lancet       Date:  2008-08-20       Impact factor: 79.321

10.  Statistical analysis of readthrough levels for nonsense mutations in mammalian cells reveals a major determinant of response to gentamicin.

Authors:  Célia Floquet; Isabelle Hatin; Jean-Pierre Rousset; Laure Bidou
Journal:  PLoS Genet       Date:  2012-03-29       Impact factor: 5.917

View more
  12 in total

1.  Pharmacophore-Based Design of New Chemical Scaffolds as Translational Readthrough-Inducing Drugs (TRIDs).

Authors:  Marco Tutone; Ivana Pibiri; Riccardo Perriera; Ambra Campofelice; Giulia Culletta; Raffaella Melfi; Andrea Pace; Anna Maria Almerico; Laura Lentini
Journal:  ACS Med Chem Lett       Date:  2020-02-18       Impact factor: 4.345

Review 2.  Nonsense suppression therapies in human genetic diseases.

Authors:  Patrícia Martins-Dias; Luísa Romão
Journal:  Cell Mol Life Sci       Date:  2021-03-22       Impact factor: 9.261

3.  Synthesis, In Vitro and In Silico Analysis of New Oleanolic Acid and Lupeol Derivatives against Leukemia Cell Lines: Involvement of the NF-κB Pathway.

Authors:  Gianfranco Fontana; Natale Badalamenti; Maurizio Bruno; Davide Castiglione; Monica Notarbartolo; Paola Poma; Alberto Spinella; Marco Tutone; Manuela Labbozzetta
Journal:  Int J Mol Sci       Date:  2022-06-13       Impact factor: 6.208

4.  Synthesis, Screening and Characterization of Novel Potent Arp2/3 Inhibitory Compounds Analogous to CK-666.

Authors:  Artem I Fokin; Roman N Chuprov-Netochin; Alexander S Malyshev; Stéphane Romero; Marina N Semenova; Leonid D Konyushkin; Sergey V Leonov; Victor V Semenov; Alexis M Gautreau
Journal:  Front Pharmacol       Date:  2022-05-30       Impact factor: 5.988

Review 5.  Suppression of Nonsense Mutations by New Emerging Technologies.

Authors:  Pedro Morais; Hironori Adachi; Yi-Tao Yu
Journal:  Int J Mol Sci       Date:  2020-06-20       Impact factor: 5.923

Review 6.  Nonsense Suppression Therapy: New Hypothesis for the Treatment of Inherited Bone Marrow Failure Syndromes.

Authors:  Valentino Bezzerri; Martina Api; Marisole Allegri; Benedetta Fabrizzi; Seth J Corey; Marco Cipolli
Journal:  Int J Mol Sci       Date:  2020-06-30       Impact factor: 5.923

7.  Caffeine boosts Ataluren's readthrough activity.

Authors:  Laura Lentini; Raffaella Melfi; Patrizia Cancemi; Ivana Pibiri; Aldo Di Leonardo
Journal:  Heliyon       Date:  2019-06-21

8.  Properties of Non-Aminoglycoside Compounds Used to Stimulate Translational Readthrough of PTC Mutations in Primary Ciliary Dyskinesia.

Authors:  Maciej Dabrowski; Zuzanna Bukowy-Bieryllo; Claire L Jackson; Ewa Zietkiewicz
Journal:  Int J Mol Sci       Date:  2021-05-07       Impact factor: 5.923

9.  In Silico Design, Synthesis, and Biological Evaluation of Anticancer Arylsulfonamide Endowed with Anti-Telomerase Activity.

Authors:  Giulia Culletta; Mario Allegra; Anna Maria Almerico; Ignazio Restivo; Marco Tutone
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-10

10.  Phytol and Heptacosane Are Possible Tools to Overcome Multidrug Resistance in an In Vitro Model of Acute Myeloid Leukemia.

Authors:  Manuela Labbozzetta; Paola Poma; Marco Tutone; James A McCubrey; Maurizio Sajeva; Monica Notarbartolo
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.